查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1941516

抗真菌藥物市場規模、佔有率和趨勢分析報告：按藥物類別、適應症、劑型、分銷管道、地區和細分市場預測（2026-2033 年）

Antifungal Drugs Market Size, Share & Trends Analysis Report By Drug Class (Azoles, Polyenes, Allylamines, Echinocandins), By Indication, By Dosage Form, By Distribution Channel, By Region, And Segment Forecasts, 2026 - 2033
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

抗真菌藥物市場概況

2025年全球抗真菌藥物市場規模估計為169.3億美元，預計2033年將達到233.9億美元。

預計從 2026 年到 2033 年，該市場將以 4.19% 的複合年成長率成長。推動市場成長的因素包括真菌感染疾病的增加趨勢，尤其是在免疫力缺乏的患者中，以及對有效治療方法日益成長的需求。

此外，抗真菌藥物研發的進步和公眾意識的提高也促進了市場擴張。由於已開發國家和開發中國家真菌感染疾病的發生率不斷上升，全球市場正經歷顯著成長。院內感染（HAI），尤其是念珠菌血症，是推動抗真菌治療需求成長的主要因素。根據世界衛生組織（WHO）2024年的報告，真菌感染疾病是全球大量院內感染的病因，而免疫力缺乏患者數量的增加，包括接受癌症治療、器官移植和免疫抑制治療的患者，加劇了這一問題。

這些感染疾病在全球日益加重，尤其是在醫療基礎設施不斷完善的地區，導致對抗真菌療法的需求持續成長。此外，多重抗藥性病原體（例如耳念珠菌）的傳播也引發了人們的擔憂，並促使人們努力研發新型、更有效的抗真菌藥物。耳Auris已被美國疾病管制與預防中心（CDC）列為2024年全球緊急健康威脅。同時，諸如足癬、甲癬和陰道念珠菌症等淺表真菌感染疾病的持續流行也使得全球對處方藥和非處方藥（OTC）抗真菌治療的需求保持穩定。

抗真菌藥物研發的技術進步是塑造市場格局的關鍵因素。新型抗真菌藥物，例如2023年核准的瑞札芬淨，可望拓展侵襲性真菌感染疾病的治療選擇。這種全身性抗真菌藥物每週只需給藥一次，因其臨床和經濟優勢，尤其是在門診治療方面，而備受關注。此外，新的治療層級和藥物也不斷研發中。例如，新型Gwt1抑制劑福斯馬諾吉匹（fosmanogepix）和針對抗藥性麴菌的奧洛芬（olorofim）等，正在應對重要的治療挑戰，尤其是在免疫力缺乏患者中。這些創新，以及分子診斷等診斷技術的持續進步，正在改善病原體的識別，並實現更具針對性的治療。因此，隨著新治療方法的引入和臨床應用，市場持續擴張，為患者和醫療系統帶來更高的療效和便利性。

儘管取得了這些進展，但由於抗真菌藥物抗藥性和治療成本不斷上漲，市場仍面臨嚴峻的挑戰。對常用抗真菌藥物（如Azole和Echinocandins）的抗藥性日益普遍。美國疾病管制與預防中心 (CDC) 2024 年的報告指出，耳Auris感染疾病急劇增加，在某些地區，Fluconazole的抗藥性率超過 90%，使其成為最難治療的病原體之一。這種廣泛的抗藥性正在削弱現有療法的有效性，並催生對價格更高的新型抗真菌藥物的需求。新型療法（如瑞札芬淨）的高成本及其在許多地區（尤其是中低收入國家）的可及性有限，是市場成長的重要障礙。此外，在資源匱乏的環境中，診斷延遲和獲得先進抗真菌治療的機會有限，加劇了真菌感染疾病帶來的公共衛生負擔。雖然藥物研發的進步帶來了希望，但確保這些治療方法的可及性和可負擔性，尤其是在服務不足的市場，對於充分發揮市場的潛力至關重要。

目錄

第1章調查方法和範圍

第2章執行摘要

第3章抗真菌藥物市場變數、趨勢和範圍

  • 市場譜系展望
  • 市場動態
  • 商業環境分析
    • 產業分析—波特五力分析
    • PESTLE分析
    • 管道分析
    • 專利到期分析
    • 定價分析

第4章抗真菌藥物市場：按藥物類別分類的業務分析

  • 按藥物類別分類的市場佔有率（2025 年和 2033 年）
  • 按藥物類別分類的市場規模、預測和趨勢分析（2021-2033 年）
  • Azole
  • Echinocandins
  • Polyenes
  • Allylamines
  • 其他

第5章抗真菌藥物市場：按適應症分類的業務分析

  • 按適應症分類的市場佔有率（2025 年和 2033 年）
  • 按適應症分類的市場規模、預測和趨勢分析（2021-2033 年）
  • 皮膚絲狀菌症
  • 麴菌症
  • 念珠菌症
  • 其他

第6章抗真菌藥物市場：按劑型分類的業務分析

  • 按劑型分類的市場佔有率（2025 年和 2033 年）
  • 按劑型分類的市場規模、預測與趨勢分析（2021-2033 年）
  • 口服藥物
  • 軟膏
  • 粉末
  • 其他

第7章抗真菌藥物市場：按分銷管道分類的業務分析

  • 按分銷管道分類的市場佔有率（2025 年和 2033 年）
  • 按分銷管道分類的市場規模、預測和趨勢分析（2021-2033 年）
  • 醫院藥房
  • 零售藥房
  • 其他藥房

第8章抗真菌藥物市場：區域估算與趨勢分析

  • 區域市場佔有率分析（2025 年和 2033 年）
  • 區域市場概覽
  • 市場規模及預測趨勢分析（2021-2033）：
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第9章 競爭情勢

  • 參與公司概況
  • 企業市場分析
  • 公司分類
  • 策略規劃
  • 公司簡介/列表
    • Bausch Health Companies Inc.
    • Pfizer, Inc.
    • Bayer AG
    • Sandoz
    • Merck &Co., Inc.
    • GSK plc.
    • Kenvue
    • GLENMARK
    • Janssen Pharmaceuticals
    • Astellas Pharma, Inc.
Product Code: GVR-1-68038-293-8

Antifungal Drugs Market Summary

The global antifungal drugs market size was estimated at USD 16.93 billion in 2025 and is projected to reach USD 23.39 billion by 2033, growing at a CAGR of 4.19% from 2026 to 2033. The market is driven by the increasing prevalence of fungal infections, particularly among immunocompromised patients, and the rising demand for effective treatment options.

In addition, advancements in antifungal drug development and growing awareness contribute to market expansion. The global market is witnessing substantial growth, driven by the increasing incidence of fungal infections across both developed and developing regions. Hospital-associated infections (HAIs), particularly candidemia, are a major contributor to the rising demand for antifungal treatments. According to the World Health Organization (WHO) in 2024, fungal infections are responsible for a significant number of hospital-related infections worldwide, exacerbated by the increasing number of immunocompromised patients, such as those undergoing cancer treatments, organ transplants, or immunosuppressive therapies.

The growing global burden of such infections, especially in regions with expanding healthcare infrastructure, contributes to sustained demand for antifungal therapies. Furthermore, the spread of multidrug-resistant pathogens like Candida auris, identified as an urgent global health threat by the CDC in 2024, has heightened concerns and prompted efforts to develop new and more effective antifungal drugs. The persistent prevalence of superficial fungal infections, such as athlete's foot, onychomycosis, and vaginal candidiasis, also ensures a steady demand for both prescription and over-the-counter (OTC) antifungal treatments globally.

Technological advancements in antifungal drug development are a key factor shaping the market landscape. The approval of novel antifungal agents, such as rezafungin in 2023, is expected to expand the treatment options available for invasive fungal infections. This systemic antifungal, which allows for once-weekly dosing, has gained attention for its clinical and economic advantages, particularly in outpatient settings. In addition, the development of new therapeutic classes and agents, such as fosmanogepix, a novel Gwt1 inhibitor, and olorofim, an orotomide targeting resistant Aspergillus species, is addressing critical gaps in treatment, particularly for immunocompromised populations. These innovations, alongside the ongoing advancements in diagnostic technologies like molecular diagnostics, are improving pathogen identification and enabling more targeted treatments. As a result, the market is expanding as new therapies are introduced and integrated into clinical practice, offering greater efficacy and convenience for patients and healthcare systems alike.

Despite these advancements, the market faces significant challenges, primarily stemming from antifungal resistance and the high costs of treatment. Resistance to commonly used antifungal agents, such as azoles and echinocandins, is becoming increasingly prevalent. The CDC's 2024 report highlights the rapid rise of Candida auris infections, with resistance rates to fluconazole exceeding 90% in some regions, making it one of the most difficult pathogens to treat. This growing resistance undermines the effectiveness of established treatments and creates a demand for newer, more expensive antifungal agents. The high cost of novel therapies, such as rezafungin, and their limited accessibility in many regions, particularly in low- and middle-income countries, presents a significant barrier to market growth. Furthermore, diagnostic delays and limited access to advanced antifungal treatments in resource-constrained settings exacerbate the public health burden of fungal infections. While advancements in drug development offer hope, the ability to make these therapies accessible and affordable, especially in underserved markets, will be crucial for realizing the full market potential.

Global Antifungal Drugs Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global antifungal drugs market report based on drug class, indication, dosage form, distribution channel, and region:

  • Drug Class Outlook (Revenue, USD Billion, 2021 - 2033)
  • Azoles
  • Echinocandins
  • Polyenes
  • Allylamines
  • Others
  • Indication Outlook (Revenue, USD Billion, 2021 - 2033)
  • Dermatophytosis
  • Aspergillosis
  • Candidiasis
  • Others
  • Dosage Form Outlook (Revenue, USD Billion, 2021 - 2033)
  • Oral Drugs
  • Ointments
  • Powders
  • Others
  • Distribution Channel Outlook (Revenue, USD Billion, 2021 - 2033)
  • Hospital Pharmacies
  • Retail Pharmacies
  • Others
  • Regional Outlook (Revenue, USD Billion, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Drug Class
    • 1.2.2. Indication
    • 1.2.3. Dosage Form
    • 1.2.4. Distribution Channel
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Antifungal Drugs Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis
    • 3.3.3. Pipeline Analysis
    • 3.3.4. Patent Expiry Analysis
    • 3.3.5. Pricing Analysis

Chapter 4. Antifungal Drugs Market: Drug Class Business Analysis

  • 4.1. Drug Class Market Share, 2025 & 2033
  • 4.2. Drug Class Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Drug Class, 2021 to 2033 (USD Billion)
  • 4.4. Azoles
    • 4.4.1. Azoles Market, 2021 - 2033 (USD Billion)
  • 4.5. Echinocandins
    • 4.5.1. Echinocandins Market, 2021 - 2033 (USD Billion)
  • 4.6. Polyenes
    • 4.6.1. Polyenes Market, 2021 - 2033 (USD Billion)
  • 4.7. Allylamines
    • 4.7.1. Allylamines Market, 2021 - 2033 (USD Billion)
  • 4.8. Others
    • 4.8.1. Other Drug Class Market, 2021 - 2033 (USD Billion)

Chapter 5. Antifungal Drugs Market: Indication Business Analysis

  • 5.1. Indication Market Share, 2025 & 2033
  • 5.2. Indication Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Indication, 2021 to 2033 (USD Billion)
  • 5.4. Dermatophytosis
    • 5.4.1. Dermatophytosis Market, 2021 - 2033 (USD Billion)
  • 5.5. Aspergillosis
    • 5.5.1. Aspergillosis Market, 2021 - 2033 (USD Billion)
  • 5.6. Candidiasis
    • 5.6.1. Candidiasis Market, 2021 - 2033 (USD Billion)
  • 5.7. Others
    • 5.7.1. Others Market, 2021 - 2033 (USD Billion)

Chapter 6. Antifungal Drugs Market: Dosage Form Business Analysis

  • 6.1. Dosage Form Market Share, 2025 & 2033
  • 6.2. Dosage Form Segment Dashboard
  • 6.3. Market Size & Forecasts and Trend Analysis, by Dosage Form, 2021 to 2033 (USD Billion)
  • 6.4. Oral Drugs
    • 6.4.1. Oral Drugs Market, 2021 - 2033 (USD Billion)
  • 6.5. Ointments
    • 6.5.1. Ointments Market, 2021 - 2033 (USD Billion)
  • 6.6. Powders
    • 6.6.1. Powders Market, 2021 - 2033 (USD Billion)
  • 6.7. Others
    • 6.7.1. Others Market, 2021 - 2033 (USD Billion)

Chapter 7. Antifungal Drugs Market: Distribution Channel Business Analysis

  • 7.1. Distribution Channel Market Share, 2025 & 2033
  • 7.2. Distribution Channel Segment Dashboard
  • 7.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2021 to 2033 (USD Billion)
  • 7.4. Hospital Pharmacies
    • 7.4.1. Hospital Pharmacies Market, 2021 - 2033 (USD Billion)
  • 7.5. Retail Pharmacies
    • 7.5.1. Retail Pharmacies Market, 2021 - 2033 (USD Billion)
  • 7.6. Other Pharmacies
    • 7.6.1. Other Pharmacies Market, 2021 - 2033 (USD Billion)

Chapter 8. Antifungal Drugs Market: Regional Estimates & Trend Analysis

  • 8.1. Regional Market Share Analysis, 2025 & 2033
  • 8.2. Regional Market Dashboard
  • 8.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
  • 8.4. North America
    • 8.4.1. North America Antifungal Drugs Market Estimates and Forecasts, By Country, 2021 - 2033 (USD Billion)
    • 8.4.2. U.S.
      • 8.4.2.1. Key Country Dynamics
      • 8.4.2.2. Target Disease Prevalence
      • 8.4.2.3. Regulatory Framework
      • 8.4.2.4. Reimbursement Framework
      • 8.4.2.5. U.S. Antifungal Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 8.4.3. Canada
      • 8.4.3.1. Key Country Dynamics
      • 8.4.3.2. Target Disease Prevalence
      • 8.4.3.3. Regulatory Framework
      • 8.4.3.4. Reimbursement Framework
      • 8.4.3.5. U.S. Antifungal Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 8.4.4. Mexico
      • 8.4.4.1. Key Country Dynamics
      • 8.4.4.2. Target Disease Prevalence
      • 8.4.4.3. Regulatory Framework
      • 8.4.4.4. Reimbursement Framework
      • 8.4.4.5. Mexico Antifungal Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 8.5. Europe
    • 8.5.1. Europe Antifungal Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 8.5.2. UK
      • 8.5.2.1. Key Country Dynamics
      • 8.5.2.2. Target Disease Prevalence
      • 8.5.2.3. Regulatory Framework
      • 8.5.2.4. Reimbursement Framework
      • 8.5.2.5. UK Antifungal Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 8.5.3. Germany
      • 8.5.3.1. Key Country Dynamics
      • 8.5.3.2. Target Disease Prevalence
      • 8.5.3.3. Regulatory Framework
      • 8.5.3.4. Reimbursement Framework
      • 8.5.3.5. Germany Antifungal Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 8.5.4. France
      • 8.5.4.1. Key Country Dynamics
      • 8.5.4.2. Target Disease Prevalence
      • 8.5.4.3. Regulatory Framework
      • 8.5.4.4. Reimbursement Framework
      • 8.5.4.5. France Antifungal Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 8.5.5. Italy
      • 8.5.5.1. Key Country Dynamics
      • 8.5.5.2. Target Disease Prevalence
      • 8.5.5.3. Regulatory Framework
      • 8.5.5.4. Reimbursement Framework
      • 8.5.5.5. Italy Antifungal Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 8.5.6. Spain
      • 8.5.6.1. Key Country Dynamics
      • 8.5.6.2. Target Disease Prevalence
      • 8.5.6.3. Regulatory Framework
      • 8.5.6.4. Reimbursement Framework
      • 8.5.6.5. Spain Antifungal Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 8.5.7. Denmark
      • 8.5.7.1. Key Country Dynamics
      • 8.5.7.2. Target Disease Prevalence
      • 8.5.7.3. Regulatory Framework
      • 8.5.7.4. Reimbursement Framework
      • 8.5.7.5. Denmark Antifungal Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 8.5.8. Sweden
      • 8.5.8.1. Key Country Dynamics
      • 8.5.8.2. Target Disease Prevalence
      • 8.5.8.3. Regulatory Framework
      • 8.5.8.4. Reimbursement Framework
      • 8.5.8.5. Sweden Antifungal Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 8.5.9. Norway
      • 8.5.9.1. Key Country Dynamics
      • 8.5.9.2. Target Disease Prevalence
      • 8.5.9.3. Regulatory Framework
      • 8.5.9.4. Reimbursement Framework
      • 8.5.9.5. Norway Antifungal Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 8.6. Asia Pacific
    • 8.6.1. Asia Pacific Antifungal Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 8.6.2. Japan
      • 8.6.2.1. Key Country Dynamics
      • 8.6.2.2. Target Disease Prevalence
      • 8.6.2.3. Regulatory Framework
      • 8.6.2.4. Reimbursement Framework
      • 8.6.2.5. Japan Antifungal Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 8.6.3. China
      • 8.6.3.1. Key Country Dynamics
      • 8.6.3.2. Target Disease Prevalence
      • 8.6.3.3. Regulatory Framework
      • 8.6.3.4. Reimbursement Framework
      • 8.6.3.5. China Antifungal Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 8.6.4. India
      • 8.6.4.1. Key Country Dynamics
      • 8.6.4.2. Target Disease Prevalence
      • 8.6.4.3. Regulatory Framework
      • 8.6.4.4. Reimbursement Framework
      • 8.6.4.5. India Antifungal Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 8.6.5. Australia
      • 8.6.5.1. Key Country Dynamics
      • 8.6.5.2. Target Disease Prevalence
      • 8.6.5.3. Regulatory Framework
      • 8.6.5.4. Reimbursement Framework
      • 8.6.5.5. Australia Antifungal Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 8.6.6. South Korea
      • 8.6.6.1. Key Country Dynamics
      • 8.6.6.2. Target Disease Prevalence
      • 8.6.6.3. Regulatory Framework
      • 8.6.6.4. Reimbursement Framework
      • 8.6.6.5. South Korea Antifungal Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 8.6.7. Thailand
      • 8.6.7.1. Key Country Dynamics
      • 8.6.7.2. Target Disease Prevalence
      • 8.6.7.3. Regulatory Framework
      • 8.6.7.4. Reimbursement Framework
      • 8.6.7.5. Thailand Antifungal Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 8.7. Latin America
    • 8.7.1. Latin America Antifungal Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 8.7.2. Brazil
      • 8.7.2.1. Key Country Dynamics
      • 8.7.2.2. Target Disease Prevalence
      • 8.7.2.3. Regulatory Framework
      • 8.7.2.4. Reimbursement Framework
      • 8.7.2.5. Brazil Antifungal Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 8.7.3. Argentina
      • 8.7.3.1. Key Country Dynamics
      • 8.7.3.2. Target Disease Prevalence
      • 8.7.3.3. Regulatory Framework
      • 8.7.3.4. Reimbursement Framework
      • 8.7.3.5. Argentina Antifungal Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 8.8. Middle East and Africa
    • 8.8.1. Middle East and Africa Antifungal Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 8.8.2. South Africa
      • 8.8.2.1. Key Country Dynamics
      • 8.8.2.2. Target Disease Prevalence
      • 8.8.2.3. Regulatory Framework
      • 8.8.2.4. Reimbursement Framework
      • 8.8.2.5. South Africa Antifungal Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 8.8.3. Saudi Arabia
      • 8.8.3.1. Key Country Dynamics
      • 8.8.3.2. Target Disease Prevalence
      • 8.8.3.3. Regulatory Framework
      • 8.8.3.4. Reimbursement Framework
      • 8.8.3.5. Saudi Arabia Antifungal Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 8.8.4. UAE
      • 8.8.4.1. Key Country Dynamics
      • 8.8.4.2. Target Disease Prevalence
      • 8.8.4.3. Regulatory Framework
      • 8.8.4.4. Reimbursement Framework
      • 8.8.4.5. UAE Antifungal Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 8.8.5. Kuwait
      • 8.8.5.1. Key Country Dynamics
      • 8.8.5.2. Target Disease Prevalence
      • 8.8.5.3. Regulatory Framework
      • 8.8.5.4. Reimbursement Framework
      • 8.8.5.5. Kuwait Antifungal Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)

Chapter 9. Competitive Landscape

  • 9.1. Participant Overview
  • 9.2. Company Market Position Analysis
  • 9.3. Company Categorization
  • 9.4. Strategy Mapping
  • 9.5. Company Profiles/Listing
    • 9.5.1. Bausch Health Companies Inc.
      • 9.5.1.1. Overview
      • 9.5.1.2. Financial Performance
      • 9.5.1.3. Product Benchmarking
      • 9.5.1.4. Strategic Initiatives
    • 9.5.2. Pfizer, Inc.
      • 9.5.2.1. Overview
      • 9.5.2.2. Financial Performance
      • 9.5.2.3. Product Benchmarking
      • 9.5.2.4. Strategic Initiatives
    • 9.5.3. Bayer AG
      • 9.5.3.1. Overview
      • 9.5.3.2. Financial Performance
      • 9.5.3.3. Product Benchmarking
      • 9.5.3.4. Strategic Initiatives
    • 9.5.4. Sandoz
      • 9.5.4.1. Overview
      • 9.5.4.2. Financial Performance
      • 9.5.4.3. Product Benchmarking
      • 9.5.4.4. Strategic Initiatives
    • 9.5.5. Merck & Co., Inc.
      • 9.5.5.1. Overview
      • 9.5.5.2. Financial Performance
      • 9.5.5.3. Product Benchmarking
      • 9.5.5.4. Strategic Initiatives
    • 9.5.6. GSK plc.
      • 9.5.6.1. Overview
      • 9.5.6.2. Financial Performance
      • 9.5.6.3. Product Benchmarking
      • 9.5.6.4. Strategic Initiatives
    • 9.5.7. Kenvue
      • 9.5.7.1. Overview
      • 9.5.7.2. Financial Performance
      • 9.5.7.3. Product Benchmarking
      • 9.5.7.4. Strategic Initiatives
    • 9.5.8. GLENMARK
      • 9.5.8.1. Overview
      • 9.5.8.2. Financial Performance
      • 9.5.8.3. Product Benchmarking
      • 9.5.8.4. Strategic Initiatives
    • 9.5.9. Janssen Pharmaceuticals
      • 9.5.9.1. Overview
      • 9.5.9.2. Financial Performance
      • 9.5.9.3. Product Benchmarking
      • 9.5.9.4. Strategic Initiatives
    • 9.5.10. Astellas Pharma, Inc.
      • 9.5.10.1. Overview
      • 9.5.10.2. Financial Performance
      • 9.5.10.3. Product Benchmarking
      • 9.5.10.4. Strategic Initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 Global Antifungal drugs market, by region, 2021 - 2033 (USD Billion)
  • Table 4 Global antifungal drugs market, by drug class, 2021 - 2033 (USD Billion)
  • Table 5 Global antifungal drugs market, by indication, 2021 - 2033 (USD Billion)
  • Table 6 Global antifungal drugs market, by dosage form, 2021 - 2033 (USD Billion)
  • Table 7 Global antifungal drugs market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 8 North America antifungal drugs market, by country, 2021 - 2033 (USD Billion)
  • Table 9 North America antifungal drugs market, by drug class, 2021 - 2033 (USD Billion)
  • Table 10 North America antifungal drugs market, by indication, 2021 - 2033 (USD Billion)
  • Table 11 North America antifungal drugs market, by dosage form, 2021 - 2033 (USD Billion)
  • Table 12 North America antifungal drugs market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 13 US antifungal drugs market, by drug class, 2021 - 2033 (USD Billion)
  • Table 14 US antifungal drugs market, by indication, 2021 - 2033 (USD Billion)
  • Table 15 US antifungal drugs market, by dosage form, 2021 - 2033 (USD Billion)
  • Table 16 US antifungal drugs market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 17 Canada antifungal drugs market, by drug class, 2021 - 2033 (USD Billion)
  • Table 18 Canada antifungal drugs market, by indication, 2021 - 2033 (USD Billion)
  • Table 19 Canada antifungal drugs market, by dosage form, 2021 - 2033 (USD Billion)
  • Table 20 Canada antifungal drugs market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 21 Mexico antifungal drugs market, by drug class, 2021 - 2033 (USD Billion)
  • Table 22 Mexico antifungal drugs market, by indication, 2021 - 2033 (USD Billion)
  • Table 23 Mexico antifungal drugs market, by dosage form, 2021 - 2033 (USD Billion)
  • Table 24 Mexico antifungal drugs market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 25 Europe antifungal drugs market, by country, 2021 - 2033 (USD Billion)
  • Table 26 Europe antifungal drugs market, by drug class, 2021 - 2033 (USD Billion)
  • Table 27 Europe antifungal drugs market, by indication, 2021 - 2033 (USD Billion)
  • Table 28 Europe antifungal drugs market, by dosage form, 2021 - 2033 (USD Billion)
  • Table 29 Europe antifungal drugs market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 30 UK antifungal drugs market, by drug class, 2021 - 2033 (USD Billion)
  • Table 31 UK antifungal drugs market, by indication, 2021 - 2033 (USD Billion)
  • Table 32 UK antifungal drugs market, by dosage form, 2021 - 2033 (USD Billion)
  • Table 33 UK antifungal drugs market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 34 Germany antifungal drugs market, by drug class, 2021 - 2033 (USD Billion)
  • Table 35 Germany antifungal drugs market, by indication, 2021 - 2033 (USD Billion)
  • Table 36 Germany antifungal drugs market, by dosage form, 2021 - 2033 (USD Billion)
  • Table 37 Germany antifungal drugs market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 38 France antifungal drugs market, by drug class, 2021 - 2033 (USD Billion)
  • Table 39 France antifungal drugs market, by indication, 2021 - 2033 (USD Billion)
  • Table 40 France antifungal drugs market, by dosage form, 2021 - 2033 (USD Billion)
  • Table 41 France antifungal drugs market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 42 Italy antifungal drugs market, by drug class, 2021 - 2033 (USD Billion)
  • Table 43 Italy antifungal drugs market, by indication, 2021 - 2033 (USD Billion)
  • Table 44 Italy antifungal drugs market, by dosage form, 2021 - 2033 (USD Billion)
  • Table 45 Italy antifungal drugs market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 46 Spain antifungal drugs market, by drug class, 2021 - 2033 (USD Billion)
  • Table 47 Spain antifungal drugs market, by indication, 2021 - 2033 (USD Billion)
  • Table 48 Spain antifungal drugs market, by dosage form, 2021 - 2033 (USD Billion)
  • Table 49 Spain antifungal drugs market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 50 Norway antifungal drugs market, by drug class, 2021 - 2033 (USD Billion)
  • Table 51 Norway antifungal drugs market, by indication, 2021 - 2033 (USD Billion)
  • Table 52 Norway antifungal drugs market, by dosage form, 2021 - 2033 (USD Billion)
  • Table 53 Norway antifungal drugs market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 54 Denmark antifungal drugs market, by drug class, 2021 - 2033 (USD Billion)
  • Table 55 Denmark antifungal drugs market, by indication, 2021 - 2033 (USD Billion)
  • Table 56 Denmark antifungal drugs market, by dosage form, 2021 - 2033 (USD Billion)
  • Table 57 Denmark antifungal drugs market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 58 Sweden antifungal drugs market, by drug class, 2021 - 2033 (USD Billion)
  • Table 59 Sweden antifungal drugs market, by indication, 2021 - 2033 (USD Billion)
  • Table 60 Sweden antifungal drugs market, by dosage form, 2021 - 2033 (USD Billion)
  • Table 61 Sweden antifungal drugs market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 62 Asia Pacific antifungal drugs market, by country, 2021 - 2033 (USD Billion)
  • Table 63 Asia Pacific antifungal drugs market, by drug class, 2021 - 2033 (USD Billion)
  • Table 64 Asia Pacific antifungal drugs market, by indication, 2021 - 2033 (USD Billion)
  • Table 65 Asia Pacific antifungal drugs market, by dosage form, 2021 - 2033 (USD Billion)
  • Table 66 Asia Pacific antifungal drugs market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 67 Japan antifungal drugs market, by drug class, 2021 - 2033 (USD Billion)
  • Table 68 Japan antifungal drugs market, by indication, 2021 - 2033 (USD Billion)
  • Table 69 Japan antifungal drugs market, by dosage form, 2021 - 2033 (USD Billion)
  • Table 70 Japan antifungal drugs market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 71 China antifungal drugs market, by drug class, 2021 - 2033 (USD Billion)
  • Table 72 China antifungal drugs market, by indication, 2021 - 2033 (USD Billion)
  • Table 73 China antifungal drugs market, by dosage form, 2021 - 2033 (USD Billion)
  • Table 74 China antifungal drugs market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 75 India antifungal drugs market, by drug class, 2021 - 2033 (USD Billion)
  • Table 76 India antifungal drugs market, by indication, 2021 - 2033 (USD Billion)
  • Table 77 India antifungal drugs market, by dosage form, 2021 - 2033 (USD Billion)
  • Table 78 India antifungal drugs market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 79 Australia antifungal drugs market, by drug class, 2021 - 2033 (USD Billion)
  • Table 80 Australia antifungal drugs market, by indication, 2021 - 2033 (USD Billion)
  • Table 81 Australia antifungal drugs market, by dosage form, 2021 - 2033 (USD Billion)
  • Table 82 Australia antifungal drugs market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 83 South Korea antifungal drugs market, by drug class, 2021 - 2033 (USD Billion)
  • Table 84 South Korea antifungal drugs market, by indication, 2021 - 2033 (USD Billion)
  • Table 85 South Korea antifungal drugs market, by dosage form, 2021 - 2033 (USD Billion)
  • Table 86 South Korea antifungal drugs market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 87 Thailand antifungal drugs market, by drug class, 2021 - 2033 (USD Billion)
  • Table 88 Thailand antifungal drugs market, by indication, 2021 - 2033 (USD Billion)
  • Table 89 Thailand antifungal drugs market, by dosage form, 2021 - 2033 (USD Billion)
  • Table 90 Thailand antifungal drugs market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 91 Latin America antifungal drugs market, by country, 2021 - 2033 (USD Billion)
  • Table 92 Latin America antifungal drugs market, by drug class, 2021 - 2033 (USD Billion)
  • Table 93 Latin America antifungal drugs market, by indication, 2021 - 2033 (USD Billion)
  • Table 94 Latin America antifungal drugs market, by dosage form, 2021 - 2033 (USD Billion)
  • Table 95 Latin America antifungal drugs market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 96 Brazil antifungal drugs market, by drug class, 2021 - 2033 (USD Billion)
  • Table 97 Brazil antifungal drugs market, by indication, 2021 - 2033 (USD Billion)
  • Table 98 Brazil antifungal drugs market, by dosage form, 2021 - 2033 (USD Billion)
  • Table 99 Brazil antifungal drugs market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 100 Argentina antifungal drugs market, by drug class, 2021 - 2033 (USD Billion)
  • Table 101 Argentina antifungal drugs market, by indication, 2021 - 2033 (USD Billion)
  • Table 102 Argentina antifungal drugs market, by dosage form, 2021 - 2033 (USD Billion)
  • Table 103 Argentina antifungal drugs market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 104 Middle East & Africa antifungal drugs market, by country, 2021 - 2033 (USD Billion)
  • Table 105 Middle East & Africa antifungal drugs market, by drug class, 2021 - 2033 (USD Billion)
  • Table 106 Middle East & Africa antifungal drugs market, by indication, 2021 - 2033 (USD Billion)
  • Table 107 Middle East & Africa antifungal drugs market, by dosage form, 2021 - 2033 (USD Billion)
  • Table 108 Middle East & Africa antifungal drugs market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 109 South Africa antifungal drugs market, by drug class, 2021 - 2033 (USD Billion)
  • Table 110 South Africa antifungal drugs market, by indication, 2021 - 2033 (USD Billion)
  • Table 111 South Africa antifungal drugs market, by dosage form, 2021 - 2033 (USD Billion)
  • Table 112 South Africa antifungal drugs market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 113 Saudi Arabia antifungal drugs market, by drug class, 2021 - 2033 (USD Billion)
  • Table 114 Saudi Arabia antifungal drugs market, by indication, 2021 - 2033 (USD Billion)
  • Table 115 Saudi Arabia antifungal drugs market, by dosage form, 2021 - 2033 (USD Billion)
  • Table 116 Saudi Arabia antifungal drugs market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 117 UAE antifungal drugs market, by drug class, 2021 - 2033 (USD Billion)
  • Table 118 UAE antifungal drugs market, by indication, 2021 - 2033 (USD Billion)
  • Table 119 UAE antifungal drugs market, by dosage form, 2021 - 2033 (USD Billion)
  • Table 120 UAE antifungal drugs market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 121 Kuwait antifungal drugs market, by drug class, 2021 - 2033 (USD Billion)
  • Table 122 Kuwait antifungal drugs market, by indication, 2021 - 2033 (USD Billion)
  • Table 123 Kuwait antifungal drugs market, by dosage form, 2021 - 2033 (USD Billion)
  • Table 124 Kuwait antifungal drugs market, by distribution channel, 2021 - 2033 (USD Billion)

List of Figures

  • Fig. 1 Antifungal drugs market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Segment snapshot
  • Fig. 10 Competitive landscape
  • Fig. 11 Antifungal drugs market dynamics
  • Fig. 12 Antifungal drugs market: Porter's five forces analysis
  • Fig. 13 Antifungal drugs market: PESTLE analysis
  • Fig. 14 Drug Class market, 2021 - 2033 (USD Billion)
  • Fig. 15 Azoles market, 2021 - 2033 (USD Billion)
  • Fig. 16 Echinocandins market, 2021 - 2033 (USD Billion)
  • Fig. 17 Polyenes market, 2021 - 2033 (USD Billion)
  • Fig. 18 Allylamines market, 2021 - 2033 (USD Billion)
  • Fig. 19 Others market, 2021 - 2033 (USD Billion)
  • Fig. 20 Indication market, 2021 - 2033 (USD Billion)
  • Fig. 21 Dermatophytosis market, 2021 - 2033 (USD Billion)
  • Fig. 22 Aspergillosis market, 2021 - 2033 (USD Billion)
  • Fig. 23 Candidiasis market, 2021 - 2033 (USD Billion)
  • Fig. 24 Others market, 2021 - 2033 (USD Billion)
  • Fig. 25 Dosage Form market, 2021 - 2033 (USD Billion)
  • Fig. 26 Oral Drugs market, 2021 - 2033 (USD Billion)
  • Fig. 27 Ointments market, 2021 - 2033 (USD Billion)
  • Fig. 28 Powders market, 2021 - 2033 (USD Billion)
  • Fig. 29 Others market, 2021 - 2033 (USD Billion)
  • Fig. 30 Distribution Channel market, 2021 - 2033 (USD Billion)
  • Fig. 31 Hospital pharmacies market, 2021 - 2033 (USD Billion)
  • Fig. 32 Retail pharmacies market, 2021 - 2033 (USD Billion)
  • Fig. 33 Other pharmacies market, 2021 - 2033 (USD Billion)
  • Fig. 34 Antifungal drugs market revenue, by region
  • Fig. 35 Regional marketplace: Key takeaways
  • Fig. 36 North America antifungal drugs market, 2021 - 2033 (USD Billion)
  • Fig. 37 U.S. country dynamics
  • Fig. 38 U.S. antifungal drugs market, 2021 - 2033 (USD Billion)
  • Fig. 39 Canada country dynamics
  • Fig. 40 Canada antifungal drugs market, 2021 - 2033 (USD Billion)
  • Fig. 41 Mexico country dynamics
  • Fig. 42 Mexico antifungal drugs market, 2021 - 2033 (USD Billion)
  • Fig. 43 Europe antifungal drugs market, 2021 - 2033 (USD Billion)
  • Fig. 44 UK country dynamics
  • Fig. 45 UK antifungal drugs market, 2021 - 2033 (USD Billion)
  • Fig. 46 Germany country dynamics
  • Fig. 47 Germany antifungal drugs market, 2021 - 2033 (USD Billion)
  • Fig. 48 France country dynamics
  • Fig. 49 France antifungal drugs market, 2021 - 2033 (USD Billion)
  • Fig. 50 Italy country dynamics
  • Fig. 51 Italy antifungal drugs market, 2021 - 2033 (USD Billion)
  • Fig. 52 Spain country dynamics
  • Fig. 53 Spain antifungal drugs market, 2021 - 2033 (USD Billion)
  • Fig. 54 Norway country dynamics
  • Fig. 55 Norway antifungal drugs market, 2021 - 2033 (USD Billion)
  • Fig. 56 Sweden country dynamics
  • Fig. 57 Sweden antifungal drugs market, 2021 - 2033 (USD Billion)
  • Fig. 58 Denmark country dynamics
  • Fig. 59 Denmark antifungal drugs market, 2021 - 2033 (USD Billion)
  • Fig. 60 Asia Pacific antifungal drugs market, 2021 - 2033 (USD Billion)
  • Fig. 61 Japan country dynamics
  • Fig. 62 Japan antifungal drugs market, 2021 - 2033 (USD Billion)
  • Fig. 63 China country dynamics
  • Fig. 64 China antifungal drugs market, 2021 - 2033 (USD Billion)
  • Fig. 65 India country dynamics
  • Fig. 66 India antifungal drugs market, 2021 - 2033 (USD Billion)
  • Fig. 67 Australia country dynamics
  • Fig. 68 Australia antifungal drugs market, 2021 - 2033 (USD Billion)
  • Fig. 69 South Korea country dynamics
  • Fig. 70 South Korea antifungal drugs market, 2021 - 2033 (USD Billion)
  • Fig. 71 Thailand country dynamics
  • Fig. 72 Thailand antifungal drugs market, 2021 - 2033 (USD Billion)
  • Fig. 73 Latin America antifungal drugs market, 2021 - 2033 (USD Billion)
  • Fig. 74 Brazil country dynamics
  • Fig. 75 Brazil antifungal drugs market, 2021 - 2033 (USD Billion)
  • Fig. 76 Argentina country dynamics
  • Fig. 77 Argentina antifungal drugs market, 2021 - 2033 (USD Billion)
  • Fig. 78 MEA antifungal drugs market, 2021 - 2033 (USD Billion)
  • Fig. 79 South Africa country dynamics
  • Fig. 80 South Africa antifungal drugs market, 2021 - 2033 (USD Billion)
  • Fig. 81 Saudi Arabia country dynamics
  • Fig. 82 Saudi Arabia antifungal drugs market, 2021 - 2033 (USD Billion)
  • Fig. 83 UAE country dynamics
  • Fig. 84 UAE antifungal drugs market, 2021 - 2033 (USD Billion)
  • Fig. 85 Kuwait country dynamics
  • Fig. 86 Kuwait antifungal drugs market, 2021 - 2033 (USD Billion)
  • Fig. 87 Company categorization
  • Fig. 88 Company market position analysis, 2024
  • Fig. 89 Strategic framework